Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by G1945Von Jan 08, 2021 6:52am
161 Views
Post# 32251949

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Press Release

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Press Release po facts: this pretty much says it all. 

"Another thing that can spark BTI is to firm up a timeline for human clinical trials so the market can begin speculating on a post human testing valuation for BTI. A near-term and credible timeline with the capital in place to get it done can unleash the speculative forces. BTI has pretty much exhausted its credibility concerning a timeline to human testing but bringing in a credible partner for xB3-001 with the capital could change everything. It would be a game-changer. Chiesi or Prothena announcing a timeline to human testing could also help. BTI finally having in place the finances to get to clinical trials can also be a big boost." 


G1945V
<< Previous
Bullboard Posts
Next >>